Provided by Tiger Trade Technology Pte. Ltd.

Hims & Hers Health Inc.

33.78
+1.926.03%
Post-market: 33.73-0.0550-0.16%19:59 EDT
Volume:14.71M
Turnover:492.64M
Market Cap:7.88B
PE:-54.22
High:34.46
Open:31.67
Low:31.60
Close:31.86
52wk High:65.30
52wk Low:13.74
Shares:233.31M
Float Shares:212.45M
Volume Ratio:1.11
T/O Rate:6.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6230
EPS(LYR):0.5123
ROE:-32.03%
ROA:-2.21%
PB:24.32
PE(LYR):65.94

Loading ...

Hims & Hers Health Is Maintained at Neutral by B of A Securities

Dow Jones
·
May 27

Moderately bullish activity in Hims and Hers Health with shares down 0.32%

TIPRANKS
·
May 27

BUZZ-BofA says Hims & Hers 2026 revenue target hinges on GLP-1 growth, lowers PT

Reuters
·
May 26

Does Medicine's New Obsession Really Work? -- Barrons.com

Dow Jones
·
May 26

BofA Adjusts Price Target on Hims & Hers Health to $25 From $28

MT Newswires Live
·
May 26

Hims & Hers : Bofa Global Research Cuts Price Objective to $25.00 From $28.00

THOMSON REUTERS
·
May 26

Does Medicine's New Obsession Really Work? -- Barron's

Dow Jones
·
May 23

Hims & Hers Health Is Maintained at Hold by Truist Securities

Dow Jones
·
May 22

Truist Adjusts Price Target on Hims & Hers Health to $23 From $18, Maintains Hold Rating

MT Newswires Live
·
May 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)

TIPRANKS
·
May 22

YieldMax HIMS ETF Declares Weekly Dividend of $0.2186 Per Share

Deep News
·
May 22

Moderately bullish activity in Hims and Hers Health with shares up 3.78%

TIPRANKS
·
May 22

Sector Update: Healthcare Stocks Rise Thursday Afternoon

MT Newswires Live
·
May 22

Hims & Hers Health to Sell Generic GLP-1 Drugs in Canada

Dow Jones
·
May 21

Hims & Hers launches generic semaglutide access in Canada from CAD 149/month

Reuters
·
May 21

Hims & Hers: Introduces Access to Generic Semaglutide for Canadian Customers

THOMSON REUTERS
·
May 21

CORRECTED-Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry

Reuters
·
May 21

Hims & Hers: IF Prescribed by a Licensed Healthcare Provider, Personalized Treatment Plans Start at C$149/Mo

THOMSON REUTERS
·
May 21

Live Longer and Better. Does Medicine's New Obsession Really Work? -- Barrons.com

Dow Jones
·
May 21

Analysts’ Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)

TIPRANKS
·
May 20